Trial Profile
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Registrational
- Sponsors Eisai Co Ltd; Eisai Inc
- 06 Dec 2022 Results from NCT00735397 and NCT01618695; assessing the long-term efficacy and safety of perampanel, patients with FOS, with or without FBTCS presented at the 76th Annual Meeting of the American Epilepsy Society
- 01 Oct 2022 Results of post-hoc analysis of open-label extension studies (Study 307, Study 235, Study 332 and Study 335) assessing long-term efficacy and safety of adjunctive perampanel in adolescent patients with focal-onset seizures (FOS), with/without focal to bilateral tonic-clonic seizures (FBTCS), or generalized tonic-clonic seizures, published in the Epilepsy and Behavior.
- 26 Apr 2022 Results of pooled analysis from Studies 307, 335, 412, 342, and 506 assessing perampanel in elderly patients presented at the 74th Annual Meeting of the American Academy of Neurology 2022